Alpha Teknova, Inc. (TKNO) stock
TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30125% above fair value
$7.77−0.44 (-5.36%)
Close on Nov 16, 2026Market cap $417.16MP/E –Yield –
Alpha Teknova operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Alpha Teknova's operating cash flow for the twelve months ending Jun 30, 2026 was -$6.27M. For fiscal 2025 it was -$8.65M. The highest annual figure on record is $2.51M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.65M | – |
| FY2024 | Dec 31, 2024 | -$12.39M | – |
| FY2023 | Dec 31, 2023 | -$18.81M | – |
| FY2022 | Dec 31, 2022 | -$27.40M | – |
| FY2021 | Dec 31, 2021 | -$9.07M | -462.0% |
| FY2020 | Dec 31, 2020 | $2.51M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$471.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$462.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.98M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.10M | – |
| Q4 FY2024 | Dec 31, 2024 | -$936.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.06M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.38M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.86M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.68M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.03M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.33M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.84M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.20M | -316.6% |
| Q4 FY2021 | Dec 31, 2021 | -$3.08M | -226.6% |
| Q3 FY2021 | Sep 30, 2021 | -$4.84M | -373.7% |
| Q2 FY2021 | Jun 30, 2021 | -$3.55M | – |
| Q1 FY2021 | Mar 31, 2021 | $2.40M | – |
| Q4 FY2020 | Dec 31, 2020 | $2.43M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.77M | – |
See a number that looks wrong?